APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Repurposing

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug Repurposing Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchDrug Repurposing Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Repurposing Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Drug Repurposing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Repurposing Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Repurposing Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drug Repurposing market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug Repurposing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug Repurposing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug Repurposing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug Repurposing is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug Repurposing include Novartis, Pfizer, AbbVie, NuMedii, Biovista, Astellas Pharma and Allergan, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug Repurposing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug Repurposing, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Repurposing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug Repurposing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Repurposing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Repurposing revenue, projected growth trends, production technology, application and end-user industry.

Drug Repurposing Segment by Company

Novartis

Pfizer

AbbVie

NuMedii

Biovista

Astellas Pharma

Allergan

Drug Repurposing Segment by Type

Neurodegenerative Diseases

CNS Diseases

Oncology

Others

Drug Repurposing Segment by Application

Hospitals

Ambulatory Surgical Centers

Others

Drug Repurposing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Repurposing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Repurposing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Repurposing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug Repurposing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug Repurposing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Repurposing revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug Repurposing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Neurodegenerative Diseases Major Player Table 3. CNS Diseases Major Player Table 4. Oncology Major Player Table 5. Others Major Player Table 6. Global Drug Repurposing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Major Player Table 8. Ambulatory Surgical Centers Major Player Table 9. Others Major Player Table 10. Drug Repurposing Industry Trends Table 11. Drug Repurposing Industry Drivers Table 12. Drug Repurposing Industry Opportunities and Challenges Table 13. Drug Repurposing Industry Restraints Table 14. Global Drug Repurposing Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Drug Repurposing Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Drug Repurposing Market Share by Region (2021-2026) Table 17. Global Drug Repurposing Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Drug Repurposing Market Share by Region (2027-2032) Table 19. Global Drug Repurposing Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Drug Repurposing Revenue Market Share by Players (2021-2026) Table 21. Global Drug Repurposing Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Drug Repurposing Key Players Headquarters & Area Served Table 23. Global Drug Repurposing Players, Product Type & Application Table 24. Global Drug Repurposing Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Drug Repurposing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Drug Repurposing Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Drug Repurposing Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Drug Repurposing Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Drug Repurposing Revenue Market Share by Type (2021-2026) Table 31. Global Drug Repurposing Revenue Market Share by Type (2027-2032) Table 32. Global Drug Repurposing Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Drug Repurposing Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Drug Repurposing Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Drug Repurposing Revenue Market Share by Application (2021-2026) Table 36. Global Drug Repurposing Revenue Market Share by Application (2027-2032) Table 37. Novartis Company Information Table 38. Novartis Business Overview Table 39. Novartis Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Novartis Drug Repurposing Product Portfolio Table 41. Novartis Recent Development Table 42. Pfizer Company Information Table 43. Pfizer Business Overview Table 44. Pfizer Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Pfizer Drug Repurposing Product Portfolio Table 46. Pfizer Recent Development Table 47. AbbVie Company Information Table 48. AbbVie Business Overview Table 49. AbbVie Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AbbVie Drug Repurposing Product Portfolio Table 51. AbbVie Recent Development Table 52. NuMedii Company Information Table 53. NuMedii Business Overview Table 54. NuMedii Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. NuMedii Drug Repurposing Product Portfolio Table 56. NuMedii Recent Development Table 57. Biovista Company Information Table 58. Biovista Business Overview Table 59. Biovista Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Biovista Drug Repurposing Product Portfolio Table 61. Biovista Recent Development Table 62. Astellas Pharma Company Information Table 63. Astellas Pharma Business Overview Table 64. Astellas Pharma Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Astellas Pharma Drug Repurposing Product Portfolio Table 66. Astellas Pharma Recent Development Table 67. Allergan Company Information Table 68. Allergan Business Overview Table 69. Allergan Drug Repurposing Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Allergan Drug Repurposing Product Portfolio Table 71. Allergan Recent Development Table 72. North America Drug Repurposing Revenue by Type (2021-2026) & (US$ Million) Table 73. North America Drug Repurposing Revenue by Type (2027-2032) & (US$ Million) Table 74. North America Drug Repurposing Revenue by Application (2021-2026) & (US$ Million) Table 75. North America Drug Repurposing Revenue by Application (2027-2032) & (US$ Million) Table 76. North America Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 77. North America Drug Repurposing Revenue by Country (2021-2026) & (US$ Million) Table 78. North America Drug Repurposing Revenue by Country (US$ Million) & (2027-2032) Table 79. Europe Drug Repurposing Revenue by Type (2021-2026) & (US$ Million) Table 80. Europe Drug Repurposing Revenue by Type (2027-2032) & (US$ Million) Table 81. Europe Drug Repurposing Revenue by Application (2021-2026) & (US$ Million) Table 82. Europe Drug Repurposing Revenue by Application (2027-2032) & (US$ Million) Table 83. Europe Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Europe Drug Repurposing Revenue by Country (2021-2026) & (US$ Million) Table 85. Europe Drug Repurposing Revenue by Country (US$ Million) & (2027-2032) Table 86. China Drug Repurposing Revenue by Type (2021-2026) & (US$ Million) Table 87. China Drug Repurposing Revenue by Type (2027-2032) & (US$ Million) Table 88. China Drug Repurposing Revenue by Application (2021-2026) & (US$ Million) Table 89. China Drug Repurposing Revenue by Application (2027-2032) & (US$ Million) Table 90. Asia Drug Repurposing Revenue by Type (2021-2026) & (US$ Million) Table 91. Asia Drug Repurposing Revenue by Type (2027-2032) & (US$ Million) Table 92. Asia Drug Repurposing Revenue by Application (2021-2026) & (US$ Million) Table 93. Asia Drug Repurposing Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Drug Repurposing Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Asia Drug Repurposing Revenue by Region (US$ Million) & (2021-2026) Table 96. Asia Drug Repurposing Revenue by Region (US$ Million) & (2027-2032) Table 97. SAMEA Drug Repurposing Revenue by Type (2021-2026) & (US$ Million) Table 98. SAMEA Drug Repurposing Revenue by Type (2027-2032) & (US$ Million) Table 99. SAMEA Drug Repurposing Revenue by Application (2021-2026) & (US$ Million) Table 100. SAMEA Drug Repurposing Revenue by Application (2027-2032) & (US$ Million) Table 101. SAMEA Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. SAMEA Drug Repurposing Revenue by Country (2021-2026) & (US$ Million) Table 103. SAMEA Drug Repurposing Revenue by Country (US$ Million) & (2027-2032) Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Drug Repurposing Image Figure 2. Global Drug Repurposing Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Repurposing Market Size Share 2021 VS 2025 VS 2032 Figure 4. Neurodegenerative Diseases Image Figure 5. CNS Diseases Image Figure 6. Oncology Image Figure 7. Others Image Figure 8. Global Drug Repurposing Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Drug Repurposing Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Image Figure 11. Ambulatory Surgical Centers Image Figure 12. Others Image Figure 13. Global Drug Repurposing Market Size (US$ Million) & (2021-2032) Figure 14. Global Drug Repurposing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Drug Repurposing Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Drug Repurposing Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Drug Repurposing Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Drug Repurposing Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Drug Repurposing Revenue Market Share by Type (2021-2032) Figure 21. Global Drug Repurposing Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Drug Repurposing Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Drug Repurposing Revenue Market Share by Application (2021-2032) Figure 24. North America Drug Repurposing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Drug Repurposing Revenue Share by Type (2021-2032) Figure 26. North America Drug Repurposing Revenue Share by Application (2021-2032) Figure 27. North America Drug Repurposing Revenue Share by Country (2021-2032) Figure 28. United States Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Drug Repurposing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Drug Repurposing Revenue Share by Type (2021-2032) Figure 33. Europe Drug Repurposing Revenue Share by Application (2021-2032) Figure 34. Europe Drug Repurposing Revenue Share by Country (2021-2032) Figure 35. Germany Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Drug Repurposing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Drug Repurposing Revenue Share by Type (2021-2032) Figure 45. China Drug Repurposing Revenue Share by Application (2021-2032) Figure 46. Asia Drug Repurposing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Drug Repurposing Revenue Share by Type (2021-2032) Figure 48. Asia Drug Repurposing Revenue Share by Application (2021-2032) Figure 49. Asia Drug Repurposing Revenue Share by Region (2021-2032) Figure 50. Japan Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Drug Repurposing Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Drug Repurposing Revenue Share by Type (2021-2032) Figure 58. SAMEA Drug Repurposing Revenue Share by Application (2021-2032) Figure 59. SAMEA Drug Repurposing Revenue Share by Country (2021-2032) Figure 60. Brazil Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Drug Repurposing Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Neurodegenerative Diseases
  • CNS Diseases
  • Oncology
  • Others
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Novartis
  • Pfizer
  • AbbVie
  • NuMedii
  • Biovista
  • Astellas Pharma
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug Repurposing Market by Type
  3. 1.2.1 Global Drug Repurposing Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Neurodegenerative Diseases
  5. 1.2.3 CNS Diseases
  6. 1.2.4 Oncology
  7. 1.2.5 Others
  8. 1.3 Drug Repurposing Market by Application
  9. 1.3.1 Global Drug Repurposing Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals
  11. 1.3.3 Ambulatory Surgical Centers
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Drug Repurposing Market Dynamics
  1. 2.1 Drug Repurposing Industry Trends
  2. 2.2 Drug Repurposing Industry Drivers
  3. 2.3 Drug Repurposing Industry Opportunities and Challenges
  4. 2.4 Drug Repurposing Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug Repurposing Market Perspective (2021-2032)
  2. 3.2 Global Drug Repurposing Growth Trends by Region
  3. 3.2.1 Global Drug Repurposing Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug Repurposing Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug Repurposing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug Repurposing Revenue by Players
  2. 4.1.1 Global Drug Repurposing Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug Repurposing Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug Repurposing Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug Repurposing Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug Repurposing Key Players Headquarters & Area Served
  7. 4.4 Global Drug Repurposing Players, Product Type & Application
  8. 4.5 Global Drug Repurposing Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug Repurposing Market CR5 and HHI
  11. 4.6.3 2025 Drug Repurposing Tier 1, Tier 2, and Tier 3
5 Drug Repurposing Market Size by Type
  1. 5.1 Global Drug Repurposing Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug Repurposing Revenue by Type (2021-2032)
  3. 5.3 Global Drug Repurposing Revenue Market Share by Type (2021-2032)
6 Drug Repurposing Market Size by Application
  1. 6.1 Global Drug Repurposing Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug Repurposing Revenue by Application (2021-2032)
  3. 6.3 Global Drug Repurposing Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Drug Repurposing Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Drug Repurposing Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Drug Repurposing Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Drug Repurposing Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 AbbVie
  14. 7.3.1 AbbVie Company Information
  15. 7.3.2 AbbVie Business Overview
  16. 7.3.3 AbbVie Drug Repurposing Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Drug Repurposing Product Portfolio
  18. 7.3.5 AbbVie Recent Developments
  19. 7.4 NuMedii
  20. 7.4.1 NuMedii Company Information
  21. 7.4.2 NuMedii Business Overview
  22. 7.4.3 NuMedii Drug Repurposing Revenue and Gross Margin (2021-2026)
  23. 7.4.4 NuMedii Drug Repurposing Product Portfolio
  24. 7.4.5 NuMedii Recent Developments
  25. 7.5 Biovista
  26. 7.5.1 Biovista Company Information
  27. 7.5.2 Biovista Business Overview
  28. 7.5.3 Biovista Drug Repurposing Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Biovista Drug Repurposing Product Portfolio
  30. 7.5.5 Biovista Recent Developments
  31. 7.6 Astellas Pharma
  32. 7.6.1 Astellas Pharma Company Information
  33. 7.6.2 Astellas Pharma Business Overview
  34. 7.6.3 Astellas Pharma Drug Repurposing Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Astellas Pharma Drug Repurposing Product Portfolio
  36. 7.6.5 Astellas Pharma Recent Developments
  37. 7.7 Allergan
  38. 7.7.1 Allergan Company Information
  39. 7.7.2 Allergan Business Overview
  40. 7.7.3 Allergan Drug Repurposing Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Allergan Drug Repurposing Product Portfolio
  42. 7.7.5 Allergan Recent Developments
8 North America
  1. 8.1 North America Drug Repurposing Revenue (2021-2032)
  2. 8.2 North America Drug Repurposing Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug Repurposing Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug Repurposing Revenue by Type (2027-2032)
  5. 8.3 North America Drug Repurposing Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug Repurposing Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug Repurposing Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug Repurposing Revenue by Application (2027-2032)
  9. 8.5 North America Drug Repurposing Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug Repurposing Revenue by Country
  11. 8.6.1 North America Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug Repurposing Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug Repurposing Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug Repurposing Revenue (2021-2032)
  2. 9.2 Europe Drug Repurposing Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug Repurposing Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug Repurposing Revenue by Type (2027-2032)
  5. 9.3 Europe Drug Repurposing Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug Repurposing Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug Repurposing Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug Repurposing Revenue by Application (2027-2032)
  9. 9.5 Europe Drug Repurposing Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug Repurposing Revenue by Country
  11. 9.6.1 Europe Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug Repurposing Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug Repurposing Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug Repurposing Revenue (2021-2032)
  2. 10.2 China Drug Repurposing Revenue by Type (2021-2032)
  3. 10.2.1 China Drug Repurposing Revenue by Type (2021-2026)
  4. 10.2.2 China Drug Repurposing Revenue by Type (2027-2032)
  5. 10.3 China Drug Repurposing Revenue Share by Type (2021-2032)
  6. 10.4 China Drug Repurposing Revenue by Application (2021-2032)
  7. 10.4.1 China Drug Repurposing Revenue by Application (2021-2026)
  8. 10.4.2 China Drug Repurposing Revenue by Application (2027-2032)
  9. 10.5 China Drug Repurposing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug Repurposing Revenue (2021-2032)
  2. 11.2 Asia Drug Repurposing Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug Repurposing Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug Repurposing Revenue by Type (2027-2032)
  5. 11.3 Asia Drug Repurposing Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug Repurposing Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug Repurposing Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug Repurposing Revenue by Application (2027-2032)
  9. 11.5 Asia Drug Repurposing Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug Repurposing Revenue by Country
  11. 11.6.1 Asia Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug Repurposing Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug Repurposing Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug Repurposing Revenue (2021-2032)
  2. 12.2 SAMEA Drug Repurposing Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug Repurposing Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug Repurposing Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug Repurposing Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug Repurposing Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug Repurposing Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug Repurposing Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug Repurposing Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug Repurposing Revenue by Country
  11. 12.6.1 SAMEA Drug Repurposing Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug Repurposing Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug Repurposing Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst